• Loading stock data…

CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference

Last Updated on March 3, 2022 by GlobeNewsWire

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.

Event: 32nd Annual Oppenheimer Healthcare ConferencePresentation: Wednesday, March 16, 2022 at 10 am EST

Management will also meet with investors during the event. Investors interested in meeting with the CinCor management team during the conference should contact their Oppenheimer & Co. representative.

About CinCor

CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.

Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO

Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: